Drug
MYK-461 clinical trials
Also written Mavacamten, MYK-461 and BMS-986427.
Keep track of what changes. Save the MYK-461 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
24 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 4
Bristol-Myers Squibb (12) · MyoKardia, Inc. (6) · LianBio LLC (2) · Xu Liu (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Second Affiliated Hospital of Nanchang University (1) · University of Manchester (1)
Studies
Open first, then newest update. How each study uses MYK-461 is read from its arms, and is right about nine times in ten.
Testing it · 24
- The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular ObstructionEnrolling by invitationPhase 4Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07103655Written as mavacamten
- Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyNot yet recruitingPhase 4Second Affiliated Hospital of Nanchang UniversityNCT07807384Written as Mavacamten
- Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH TrialRecruitingNot applicableUniversity of ManchesterNCT07120776Written as Camzyos (Mavacamten)
- A Study of Mavacamten in Non-Obstructive Hypertrophic CardiomyopathyTerminatedPhase 3Bristol-Myers SquibbNCT05582395Written as Mavacamten
- A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyActive, not recruitingPhase 4Bristol-Myers SquibbNCT06112743Written as Mavacamten
- A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)Active, not recruitingPhase 4Bristol-Myers SquibbNCT07004972Written as Mavacamten
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMCompletedPhase 2/3Bristol-Myers SquibbNCT03723655Written as mavacamten
- A Study of Mavacamten in Obstructive Hypertrophic CardiomyopathyCompletedPhase 3Bristol-Myers SquibbNCT05414175Written as Mavacamten
- A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic CardiomyopathyActive, not recruitingPhase 3Bristol-Myers SquibbNCT06253221Written as Mavacamten
- A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction TherapyCompletedPhase 3Bristol-Myers SquibbNCT04349072Written as Mavacamten
- Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic CardiomyopathyActive, not recruitingNot applicableXu LiuNCT06947590Written as mavacamten
- A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnTCompletedPhase 2Bristol-Myers SquibbNCT04766892Written as mavacamten
- Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEERCompletedPhase 2Bristol-Myers SquibbNCT03496168Written as mavacamten
- A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCMCompletedPhase 3LianBio LLCNCT05174416Written as Mavacamten
- Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese SubjectsCompletedPhase 1LianBio LLCNCT05135871Written as Mavacamten
- A Study to Evaluate the Effects of Mavacamten in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05719805Written as Mavacamten
- A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05362045Written as Mavacamten
- A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05320094Written as Mavacamten
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)CompletedPhase 2MyoKardia, Inc.NCT03442764Written as mavacamten
- Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyCompletedPhase 3MyoKardia, Inc.NCT03470545Written as mavacamten
See all 24 studies that test MYK-461 →
Given in every arm · 1 — MYK-461 is usual care beside what is tested
Codes
What other systems call MYK-461 · ClinicalTrials.gg INT000419
- MeSH (NLM) C000605992MYK-461Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) QX45B99R3JMAVACAMTENConfirmed FDA, NLM
- RxNorm 2600867One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000605992 | MYK-461 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | QX45B99R3J | MAVACAMTEN | Confirmed FDA, NLM |
| RxNorm | 2600867 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.